Moderna Stock: Buy, Sell, or Hold? The Motley Fool

According to 17 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $82.07, which is an increase of 89.15% from the latest price. He projected Recursion will offer more information on cost-cutting when it reports fourth quarter 2024 results early in the new year. Earlier this month, the company swung to a surprise profit and topped revenue estimates for the third quarter following the launch earlier this year of its updated COVID-19 vaccine. “We expect to end the year with $9 billion in cash,” Talukdar said, according to a transcript provided by AlphaSense. “Our investment rate … is declining each year going forward. And we anticipate that $9 billion will have us launching 10 products over the next three years that will start to contribute to revenue a year after approval.”

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… Marks cited FDA cooperation with Operation Warp Speed initiative, through which Trump’s first administration shepherded development of COVID-19 vaccines through funding of trials and manufacturing.

MRNA Stock Analysis – Frequently Asked Questions

This is different than traditional vaccines where a harmless version of a virus or bacteria is used to trigger an immune response. Moderna had been working on this technology for nearly a decade before the pandemic broke out, putting the company in a position to get a vaccine to market very quickly. However, last month, Moderna surprised analysts by reporting net income of $13 million (up from a $3.63 billion net loss in Q3 2023) and higher-than-expected sales of its COVID-19 vaccine Spikevax® ($1.8 billion). Yet the unexpected profit wasn’t enough to stave off a drop in Moderna shares. Unlock your free copy of MarketBeat’s comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you’ll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street’s top analysts.

Stock Analysis

According to a 2021 study, Operation Warp Speed spent over $18 billion dollars of U.S. public funds on six vaccine candidates, including Moderna’s SpikeVax, the subject of a $1.5 billion agreement announced in August 2020 to manufacture and deliver 100 million doses. There’s no doubt that the success of the COVID-19 vaccine was proof that mRNA technology is a viable path to pursue for Moderna, which took a lot of the risk out of an investment in the company. That said, it’s worth remembering that this is a very difficult and capital-intensive business, with binary outcomes for the drugs that take millions of dollars to develop. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. But it’s fxtm review important to take a long-term view with Moderna, and also look at some of its positive points. It’s good to see the company prioritizing and adjusting its strategy to reach its goals — even if certain ones, like breakeven, won’t come as soon as we’d hoped.

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively. Discover which analysts rank highest on predicting the directional movement of MRNA.

Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Select to analyze similar companies using key performance metrics; select up to 4 stocks. “If you listen to where his stance is on vaccines most recently, so starting— dating from 2022 and as recently as shortly after the election results, he is a lot more moderate than I would have thought,” she said.

Discover which analysts rank highest on predicting the price target how to become a web developer of MRNA. Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement. While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

Price Score

Nearly four years later, the company is in a curious spot as it still has only one commercially available product. Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic Forex arbitrage acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. In the 2024 presidential election’s latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme…

But flu vaccines, COVID shots, and RSV vaccines may not be enough to make the business profitable in the long run. Moderna (MRNA 3.19%) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with revenue from its vaccine diminishing and no longer being a strong growth catalyst, investors have become bearish on the healthcare stock.

• And the biotech aims to file for regulatory approval of three potential products by the end of the year — a next-generation coronavirus vaccine, a combined influenza/coronavirus vaccine, and an RSV vaccine for younger high-risk adults.
• Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Moderna by 11.6% in the 3rd quarter.
• ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after buying an additional 109,852 shares during the last quarter.
• Discover which analysts rank highest on predicting the directional movement of MRNA.

Company Insights: MRNA

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Moderna (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018.

Moderna Recently Swung To Surprise Q3 Profit

Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after buying an additional 29,566 shares during the period. ARK Investment Management LLC grew its position in shares of Moderna by 10.4% during the 3rd quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after buying an additional 109,852 shares during the last quarter.